Ng George K 4

What Happened
CEO George K. Ng reported an acquisition of 2,034 shares of Processa Pharmaceuticals (PCSA) on 2026-04-30. The filing lists a purchase price of $2.69 per share for a total cash outlay of $5,471. This was a straight purchase (transaction code P), which is typically viewed as a more bullish-type insider activity than a sale.

Key Details

• Transaction date and price: 2026-04-30 — 2,034 shares at $2.69 each.
• Total value: $5,471 (approx.).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes / plan: No 10b5-1 plan, tax withholding, or other special notations were reported in the supplied summary.
• Filing timeliness: Report filed 2026-05-01 (appears timely; Form 4 is generally due within two business days).

Context
The filing uses code "P" (purchase), which covers open-market or private purchases; the filing does not specify whether this was executed under a trading plan. This transaction is a straightforward equity purchase (not an option exercise, gift, or award). The dollar amount is modest, so while purchases are generally more informative than sales, this single small buy should be weighed alongside other insider activity and company developments.